Şunu aradınız:: cholestase (Danca - İngilizce)

hepatitis, gulsot, cholestase
hepatitis, jaundice, cholestasis

ikke kendt: cholestase, hepatomegali.
not known: cholestasis, hepatomegaly.

alvorlig leverfunktionsnedsættelse, biliær cirrhose og cholestase
severe hepatic impairment, biliary cirrhosis and cholestasis

leverfunktion, cholestase og gulsot, skade på cholangitis
hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis

alvorligt nedsat leverfunktion, biliær cirrhose eller cholestase.
severe hepatic impairment, biliary cirrhosis or cholestasis.

galdegangssygdomme, skade på leverceller og hepatitis, cholestase og gulsot
bile duct disorders, hepatocellular damage and hepatitis, cholestasis and jaundice

der findes ingen tilgængelige data for patienter med svær baseline cholestase.
no data are available for patients with severe baseline cholestasis.

hepatitis fulminant hepatitis (herunder uhelbredelige tilfælde) gulsot cholestase
hepatitis fulminant hepatitis (including fatal cases) jaundice cholestasis

hos patienter med konstateret cholestase kan eksponeringen for den aktive metabolit være forhøjet.
in patients with evidence of the presence of cholestasis, the exposure to the active metabolite may be increased.

cholestase og leverenzymstigning, anses for at være relateret til øget galdesekretion hos denne dyreart.
toxicities observed in dogs at levels similar to human exposure at the maximum recommended dose were liver changes, including bile thrombi, cholestasis and liver enzyme elevations thought to be related to increased bile secretion in this species.

unormal leverenzymtal og funktion, cholestase og gulsot, skade på leverceller og hepatitis, cholangitis
and function abnormalities, cholestasis and

den maximale anbefalede dosis til patienter med mildt til moderat nedsat leverfunktion uden cholestase er 80 mg valsartan.
in patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan.

unormale leverenzymtal og leverfunktion, cholestase og gulsot, skade på leverceller og hepatitis, cholangitis trombose i leverarterie, venokklusiv leversygdom leversvigt, galdevejsstenose
hepatic enzymes and function abnormalities, cholestasis and jaundice, hepatocellular damage and hepatitis, cholangitis hepatitic artery thrombosis, venoocclusive liver disease hepatic failure, bile duct stenosis

alvorlig nyrefunktionsnedsættelse (kreatininclearance 30 ml/min) , refraktær hypokaliæmi, hypercalcæmi, alvorlig leverfunktionsnedsættelse, biliær cirrhose og cholestase.
severe renal impairment (creatinine clearance 30 ml/min) , refractory hypokalaemia, hypercalcaemia, severe hepatic impairment, biliary cirrhosis and cholestasis.

entresto er kontraindiceret hos patienter med svært nedsat leverfunktion, biliær cirrhose eller cholestase (child-pugh klasse c) (se pkt.
entresto is contraindicated in patients with severe hepatic impairment, biliary cirrhosis or cholestasis (child-pugh c classification) (see section 4.3).

kinzalkomb bør ikke gives til patienter med cholestase, biliære obstruktive sygdomme eller svær leverinsufficiens (se pkt.4. 3) , idet telmisartan overvejende udskilles med galden.
kinzalkomb should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.